Last reviewed · How we verify
Mid-Dose Cohort
At a glance
| Generic name | Mid-Dose Cohort |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
- Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy (PHASE1)
- A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) (PHASE1, PHASE2)
- A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia (PHASE1, PHASE2)
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV (PHASE1)
- CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy (PHASE1, PHASE2)
- Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease (PHASE1, PHASE2)
- First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mid-Dose Cohort CI brief — competitive landscape report
- Mid-Dose Cohort updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI